logo-loader
viewVerona Pharma

Verona Pharma plc: Issue of Equity and Total Voting Rights

LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it yesterday issued 887,080 Ordinary Shares of 5 pence each (the “New Ordinary Shares”) following the vesting of restricted stock units held by former employees in the Company, Jan-Anders Karlsson and Piers Morgan.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on March 26, 2020 (“Admission”).

Total voting rights

Following Admission, the Company will have a total of 106,213,718 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 106,213,718 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communications[email protected]
  
N+1 SingerTel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
 
  

 

Quick facts: Verona Pharma

Price: 41

Market: AIM
Market Cap: £43.66 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Smiths Group halts planned demerger of medical arm

Headlines from the Proactive UK newsroom. Smiths Group (LON:SMIN) has halted the planned demerger of its medical arm due to the coronavirus crisis. Smiths Medical needs to concentrate on the delivery of ventilators and other critical care devices, though the intention remains to separate once...

on 31/3/20